API | taspoglutide

taspoglutide Report issue

Biologics Peptide Experimental

AACT ChEMBL MeSH PubChem

Active Ingredient History

NOW

Taspoglutide is a former experimental drug, a glucagon-like peptide-1 agonist, that was under investigation for treatment of type 2 diabetes and being codeveloped by Ipsen and Roche. ^Wikipedia

Chemistry

SMILES: Missing data
InChIKey: Missing data
Mol. Mass: Missing data
ALogP: Missing data
ChEMBL Molecule:
taspoglutide

More Chemistry

Pharmacology

Mechanism of Action:
- Glucagon-like peptide 1 receptor (Homo sapiens) ^UniProt
Multi-specific: No
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

bim51077 | bim 51077 | bim-51077 | bim51079 | bim 51079 | bim-51079 | bim51182 | bim 51182 | bim-51182 | itm077 | itm 077 | itm-077 | r 1583 | r-1583 | r1583 cpd | ro-5073031 | taspoglutide

Organizations (1)

Research & Development (1)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (1)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (1)

Diabetes Mellitus, Type 2 (Phase 3)

Overview

Highest Phase: Phase 3
# of Trials: 13
# of Trial Organizations: 1

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue